Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats

Drug Metabolism and Disposition

Volumn 35, Issue 1, 2007, Pages 110-115

  Zhang, Wenxia ^a   Tan, Theresa May Chin ^a   Lim, Lee Yong ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELIPROLOL; CURCUMIN; CYTOCHROME P450 3A; GLYCOPROTEIN P; MIDAZOLAM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELIPROLOL; COLORING AGENTS; CURCUMIN; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; INTESTINE, SMALL; KIDNEY; LIVER; MALE; MIDAZOLAM; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33845937786     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011072     Document Type: Article

References (40)

1. Ammon HPT and Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57:1-7.
2. Anuchapreeda S, Leechanachai P, Smith M, Ambudkar SV, and Limtrakul P (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug resistant human KB cells. Biochem Pharmacol 64:573-582.
3. Caudron E, Laurent S, Billaud EM, and Prognon P (2004) Simultaneous determination of the acid/base antihypertensive drugs celiprolol, bisoprolol and irbesartan in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 801:339-345.
4. Chaobal HN and Kharasch ED (2005) Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 78:529-539.
5. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900.
6. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, and Houin G (2004) Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm (Amst) 278:119-131.
7. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, and Giardiello FM (2006) Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4:1035-1038.
8. Doherty JE, Dalrymple GV, Murphy ML, Kane JJ, Bissett JK, and de Soyza N (1977) Pharmacokinetics of digoxin. Fed Proc 36:2242-2246.
9. Dresser GK, Schwartz UI, Wilkinson GR, and Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 73:41-50.
10. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, and Fattinger K (2000) St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598-604.
11. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190.
12. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
13. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, and Cheboyina S (2006) Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69-74.
14. Hartmann G, Vassileva V, and Piquette-Miller M (2005) Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab Dispos 33:820-828.
15. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, Farmer PB, Steward WP, and Gescher AJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11:105-111.
16. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, and Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 66:338-345.
17. Kanazu T, Okamura N, Yamaguchi Y, Baba T, and Koike M (2005) Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats. Xenobiotica 35:305-317.
18. Karlsson J, Kuo SM, Ziemniak J, and Artursson P (1993) Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol 110:1009-1016.
19. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res (NY) 16:408-414.
20. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, and Greenblatt DJ (2002) In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237.
21. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
22. Lilja JJ, Backman JT, Laitila J, Luurila H, and Neuvonen PJ (2003) Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73:192-198.
23. Liu DY, Yang M, Zhu HJ, Zheng YF, and Zhu XQ (2006) Human pregnane X receptor-mediated transcriptional regulation of cytochrome P450 3A4 by some phytochemicals. Zhejiang Da Xue Xue Bao Yi Xue Ban 35:8-13.
24. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955.
25. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, et al. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
26. Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, et al. (2003) Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 31:1170-1175.
27. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, and Roots I (2004) Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 76:330-340.
28. Mountfield RJ, Senepin S, Schleimer M, Walter I, and Bittner B (2000) Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. Int J Pharm (Amst) 211: 89-92.
29. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, and Falloon J (2002) The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234-238.
30. Pruss TP, Lamon KD, and Hagen NS (1988) Celiprolol - overview of 6 years of clinical trials experience. J Int Med Res 16:17A-22A.
31. Ravindranath V and Chandrasekhara N (1980) Absorption and tissue distribution of curcumin in rats. Toxicology 16:259-265.
32. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854.
33. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, and Steward WP (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900.
34. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590.
35. ter Horst PG, Foudraine NA, Cuypers G, van Dijk EA, and Oldenhof NJ (2003) Simultaneous determination of levomepromazine, midazolam and their major metabolites in human plasma by reversed-phase liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 791:389-398.
36. Tindle HA, Davis RB, Phillips RS, and Eisenberg DM (2005) Trends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 11:42-49.
37. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
38. Warrington JS, Greenblatt DJ, and von Moltke LL (2004) The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 309:730-736.
39. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, and Schuetz EG (2002) Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303:323-332.
40. Zhang H, Yao M, Morrison RA, and Chong S (2003) Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res (NY) 26:768-772.